Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for the combination of SHR-1501 with adebrelimab (SHR-1316) for the treatment of non-muscle invasive bladder cancer.
Adebrelimab: A PD-L1 Monoclonal Antibody with Established Efficacy
Hengrui’s adebrelimab is a programmed death-ligand 1 (PD-L1) monoclonal antibody that has been approved in China for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy since March of last year. This approval marks another significant step in the expansion of adebrelimab’s potential indications.
SHR-1501: Interleukin-15 (IL-15) for Advanced Cancer Treatments
SHR-1501 is interleukin-15 (IL-15), a cytokine within the chemokine family, which is being developed for the treatment of advanced solid tumors and hematological tumors. IL-15 is noted for its ability to avoid stimulating Treg proliferation and inducing T cell apoptosis, which are limitations associated with IL-2.
Combining Therapies for Enhanced Efficacy
The combination of SHR-1501 and adebrelimab represents a strategic approach to enhance the treatment of non-muscle invasive bladder cancer. This therapy aims to leverage the distinct mechanisms of action of each component to improve patient outcomes.-Fineline Info & Tech
